datopotamab deruxtecan investigational
Selected indexed studies
- Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. (Cancer Treat Rev, 2024) [PMID:38502995]
- Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. (J Clin Oncol, 2024) [PMID:38652877]
- Antibodies to watch in 2025. (MAbs, 2025) [PMID:39711140]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. (2024) pubmed
- Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. (2024) pubmed
- Antibodies to watch in 2024. (2024) pubmed
- Antibodies to watch in 2025. (2025) pubmed
- Antibodies to watch in 2023. (2023) pubmed
- Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. (2024) pubmed
- TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. (2023) pubmed
- Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. (2025) pubmed
- Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. (2025) pubmed
- TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. (2024) pubmed